BD, 772502, RY655 Mouse Anti-Human CD47 CC2C6

Name: RY655 Mouse Anti-Human CD47 CC2C6
Brand: BD
SKU: 772502

50 µg

Catalog Number: 772502

Pricing

Request a quote.

View RFQ List

Category

Cell Cycle Reagents

TagsReagents Flow Cytometry Reagents research-reagents

CollectionsBD Flow Cytometry Reagents for Multicolor Panels BD Single-Cell Multiomics Reagents for the BD Rhapsody™ Platform BD Immunoassay Reagents: CBA, ELISA & ELISPOT for Cytokine Panels

Manufacturer's Pagewww.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/ry655-mouse-anti-human-cd47.772502

Description

The CC2C6 monoclonal antibody specifically recognizes CD47 which is also known as Integrin-associated protein (IAP), Rh-related antigen, Ovarian carcinoma antigen (OA3), MER6, or neutrophilin. CD47 is a 42-52 kDa N-linked glycan protein which has an extracellular N-terminal IgV-like domain followed by 5 transmembrane segments and a short C-terminal cytoplasmic domain. CD47 is expressed on all hematopoietic cells, including leucocytes, platelets, and erythrocytes except for Rh-negative erythrocytes. It is also expressed on epithelial cells, endothelial cells, fibroblasts, and many tumor cell lines. CD47 binds to and activates the inhibitory Signal regulatory protein α (SIRPα) expressed on phagocytic cells. This trans interaction inhibits phagocytosis and protects CD47-positive cells, including "self" blood cells like erythrocytes, from phagocytosis. CD47 binds to thrombospondin-1 which regulates cell adhesion and migration and plays a role in the regulation of inflammation and angiogenesis. CD47 can also interact with integrins which can affect various cellular functions including cellular adhesion, spreading, and migration. The CC2C6 antibody can reportedly inhibit the interaction between CD47 and SIRPα.
Bead-based compensation or unmixing controls, such as BD® CompBeads or BD™ SpectraComp™, can be used as surrogates to assess fluorescence spillover when bound to fluorochrome-conjugated antibodies. Although these beads have spectral properties similar to cells, variations in spectral emission may occur, resulting in differing spillover values compared to biological controls. Therefore, it is considered best practice to compare the spillover obtained from cells and bead-based controls when using BD® CompBeads or BD™ SpectraComp™ for the first time, to ensure they are appropriate for the intended application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
11. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
12. Tandem fluorochromes contain both an energy donor and an energy acceptor. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from the donor may be observed. Additionally, multi-laser cytometers may directly excite both the donor and acceptor fluorochromes. Therefore, we recommend for every tandem conjugate, a matched individual single-stain control be acquired for generating a compensation or spectral unmixing matrix.
13. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.

Specifications

General

Source	Human PD-L2, amino acids (Leu20-Pro219) (Accession # Q9BQ51) was expressed in 293E cells. The carboxyl-terminus contains a linker-IgG Fc-6His tag.
Molecular Mass	The 445 amino acid recombinant protein has a predicted molecular mass of approximately 50.2 kD. The DTT-reduced and non-reduced protein migrate at approximately 70 kD and 140 kD respectively by SDS-PAGE. The predicted N-terminal amino acid is Leu.
Purity	> 95% by SDS-PAGE gel as determined by Coomassie stained SDS-PAGE and HPLC analyses.
Formulation	0.22 µm filtered protein solution is in PBS pH 7.2.
Endotoxin Level	Less than 0.10 EU per µg of protein as determined by the LAL method.
Concentration	10-25 µg sizes are bottled at 200 µg/mL. 100 µg and larger size are bottled at the concentration indicated on the vial.
Storage & Handling	Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.